Raymond James Financial Inc. Makes New $1.16 Million Investment in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Raymond James Financial Inc. acquired a new stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 150,967 shares of the company's stock, valued at approximately $1,159,000. Raymond James Financial Inc. owned about 0.41% of iTeos Therapeutics at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Clear Harbor Asset Management LLC bought a new position in shares of iTeos Therapeutics during the fourth quarter valued at $96,000. Virtu Financial LLC acquired a new stake in iTeos Therapeutics in the third quarter valued at $102,000. SG Americas Securities LLC raised its position in iTeos Therapeutics by 12.2% during the 4th quarter. SG Americas Securities LLC now owns 13,866 shares of the company's stock worth $106,000 after purchasing an additional 1,508 shares during the last quarter. Marquette Asset Management LLC acquired a new position in iTeos Therapeutics during the 4th quarter worth about $122,000. Finally, Wells Fargo & Company MN grew its position in shares of iTeos Therapeutics by 16.9% in the 4th quarter. Wells Fargo & Company MN now owns 16,644 shares of the company's stock valued at $128,000 after buying an additional 2,402 shares during the last quarter. 97.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Wedbush reaffirmed an "outperform" rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research note on Wednesday, March 5th. JPMorgan Chase & Co. dropped their price target on shares of iTeos Therapeutics from $22.00 to $15.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th. Wells Fargo & Company decreased their price objective on shares of iTeos Therapeutics from $17.00 to $16.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Finally, HC Wainwright restated a "buy" rating and issued a $46.00 target price on shares of iTeos Therapeutics in a report on Thursday, March 6th.

iTeos Therapeutics Stock Performance

Shares of iTeos Therapeutics stock traded down $0.02 on Friday, reaching $6.68. 253,464 shares of the company's stock were exchanged, compared to its average volume of 469,732. The company has a market capitalization of $255.67 million, a P/E ratio of -2.12 and a beta of 1.39. iTeos Therapeutics, Inc. has a 52 week low of $4.80 and a 52 week high of $18.70. The firm's 50-day moving average is $6.55 and its two-hundred day moving average is $7.44.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its earnings results on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.94) by $0.14. On average, analysts expect that iTeos Therapeutics, Inc. will post -3.49 EPS for the current fiscal year.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.